PHARMACEUTICAL INNOVATION SERVICES SL
Company details
- Active NIF/CIF: B85793164
-
-
-
-
Address: C. de Luis Martinez Feduchi, 32, Hortaleza, 28055 Madrid, España See in map
-
-
Featured products:
More information on PHARMACEUTICAL INNOVATION SERVICES SL
-
20/10/2022 | BORME act no.: 460634 | Register: MADRIDCambio de objeto social
-
20/03/2020 | BORME act no.: 128072 | Register: MADRIDCambio de domicilio social
-
22/10/2010 | BORME act no.: 879085 | Register: MADRIDDepósito de cuentas anuales (Octubre de 2010)
-
29/10/2009 | BORME act no.: 452448 | Register: MADRIDConstitución
-
29/10/2009 | BORME act no.: 452448 | Register: MADRIDNombramientos
Other information
The CIF of PHARMACEUTICAL INNOVATION SERVICES SL is B85793164 and its current business status is active. Its economic sector is within the CNAE 7219 - Otra investigación y desarrollo experimental en ciencias naturales y técnicas. Its SIC classification is 8731 - Investigación física comercial.
PHARMACEUTICAL INNOVATION SERVICES SL employs approximately Between 1 and 9 employees and generates an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Madrid. To date, it has 1 registration charges. Its most recent announcement in the Borme was published on 20/10/2022 and its last deposit of ordinary annual accounts corresponds to the year 2023.
You can access the contact information of PHARMACEUTICAL INNOVATION SERVICES SL, such as the telephone number, postal address, and website, in the Company Data section.
If you wish to obtain more information about PHARMACEUTICAL INNOVATION SERVICES SL, you can review one of our available financial reports, the Annual Accounts of the company, or check if it has any registered payment incidents in the RAI delinquency file.
The financial, commercial, and legal information of PHARMACEUTICAL INNOVATION SERVICES SL comes from official data sources and is automatically updated every day.
Do you want to know more about PHARMACEUTICAL INNOVATION SERVICES SL??
Find out more about this company by consulting these reports: